Clinical Trials

86 enrolled

Prostatic Neoplasms

NCT05675410 2026-05-27

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06124157 2026-05-27

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

222 enrolled

Burkitt Lymphoma

NCT06136650 2026-05-27

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

30 enrolled

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT06353386 2026-05-26

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT03223610 2026-05-22

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

155 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06317662 2026-05-22

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06717347 2026-05-22

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-22

MK-2140-011

594 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06925737 2026-05-22

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Other hematologic neoplasm

27 enrolled

Leukemia

NCT06091254 2026-05-19

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06952803 2026-05-19

EvoPAR-PR02

700 enrolled

Prostatic Neoplasms

NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Prostatic Neoplasms

NCT06091865 2026-05-15

OLYMPIA-3

904 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06564038 2026-05-14

Soundtrack-E

408 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

16 enrolled

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT06649812 2026-05-13

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

120 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06738368 2026-05-12

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

30 enrolled

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07225946 2026-05-11

KLK2-PASenger

800 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT05818683 2026-05-08

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

300 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT04043494 2026-05-06

LBL 2018

683 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06043323 2026-05-06

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

20 enrolled

Lymphoma, Follicular

NCT06191744 2026-05-06

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

5,951 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT05848765 2026-05-05

REFRACT

284 enrolled

Lymphoma, Lymphoma, Follicular

NCT06136624 2026-05-05

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07005154 2026-05-01

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT04739813 2026-04-29

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05389423 2026-04-28

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT06249191 2026-04-24

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07097363 2026-04-23

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

18 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06378866 2026-04-20

DIVINE

532 enrolled

Prostatic Neoplasms

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

224 enrolled

Lymphoma, B-Cell

NCT07224100 2026-04-16

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

33 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07237269 2026-04-15

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

140 enrolled

Prostatic Neoplasms

NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

40 enrolled

Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

DermatologicLymphoidOther hematologic neoplasm

22 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT07221838 2026-04-09

OCTAGON

Phase 4 Recruiting

75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT04787744 2026-04-08

VA STARPORT

Phase 2/3 Recruiting

464 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT07493148 2026-03-25

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06457919 2026-03-24

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

50 enrolled

Prostatic Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

GastrointestinalGynecologic

454 enrolled

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types